
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Concerto Receives FDA IND Clearance for Live Biotherapeutic for Atopic Dermatitis
Details : ENS-002 is an investigational live biotherapeutic product (LBP) applied topically, being investigated to treat atopic dermatitis (AD).
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 26, 2024
Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical ENS-002 for Atopic Dermatitis in Adults
Details : ENS-002 is a Probiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
June 21, 2024
Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Study Phase : Discovery
Sponsor : Safar Partners
Deal Size : $23.0 million
Deal Type : Series A Financing
Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline
Details : The company’s first microbial product, “Ensemble No.2” (ENS-002), is designed to rehabilitate the skin microbiome. By taming the pathogenic behaviors of Staphylococcus aureus, ENS-002 may decrease the frequency and severity of eczema flares.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Undisclosed
November 02, 2022
Lead Product(s) : ENS-002
Therapeutic Area : Dermatology
Highest Development Status : Discovery
Sponsor : Safar Partners
Deal Size : $23.0 million
Deal Type : Series A Financing
